retatrutide safety clinical trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a retatrutide clinical trials safety retatrutide

CONCLUSIONS The Namgok Award is the highest scientific award of the Korean Endocrine Society, and is given to honor an individual who has made excellent contributions to progress in the field of endocrinology and metabolism

Yatsunami, R., Ando, A., Yang, Y., Takaichi, S., Kohno, M., Matsumura, Y., Ikeda, H., Fukui, T., Nakasone, K., Fujita, N., & Sekine, M

Despite the CV benefits of some GLP-1 RAs [34,35,36,37,38], there was no difference in the prescribing rates of GLP-1 RAs between people with and without CV disease history [30]

Once symptoms resolve, re-titration using a slower dose-escalation schedule may improve long-term tolerability

The FDA requires that these products demonstrate safety, efficacy, and manufacturing quality before they can be marketed